TrialBreast cancer research and treatment2017

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.

M Higgins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.